Recomendaciones para la profilaxis postexposición no ocupacional al VIH

Secretaría del Plan Nacional sobre el sida. Registros autonómicos de casos de sida, Centro Nacional de Epidemiología. Vigilancia Epidemiológica del sida en España. Registro Nacional. Informe semestral n.° 1, año 2000. Disponible en: http://www.msc.es/sida/epidemiologia/actualizada/2000-01.dpf 1999, Catalonia (Spain) Departament de Sanitat i Seguretat Social 1998, CDC. Centers for Disease Control and Prevention (United States). Public Health Service Guidelines for the Management of Health Care Workers Exposures to HIV and Recommendations for Postexposure Prophylaxis, Morb Mortal Wkly Rep, 47, 1 1998, Centre d’Estudis Colegials. Normes d’actuació després d’una exposició accidental a sang o altres fluids biològics en el medi sanitari. Quaderns de la bona Praxi. Col·legi Oficial de Metges de Barcelona, Desembre, 9, 1 1997, Grupo Español de Registro de Accidentes en Trabajadores de Atención de Salud Miró, 2000, Enferm Infecc Microbiol Clin, 18, 396 1998 Wade, 1998, Abbreviated Regimens of Zidovudine Prophylaxis and Perinatal Transmission of the Human Immunodeficiency Virus, N Engl J Med, 339, 1409, 10.1056/NEJM199811123392001 1995, CDC, Centers for Disease ControlPrevention (United States). Case-control study of HIV seroconversion in health-care workers after percutaneous exposure to HIV -infected blood. France, United Kingdom and United States, January 1988-August 1994, Morb Mortal Wkly Rep, 44, 929 Tsai, 1993, Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus, J Aids, 10, 1086 Grob, 1997, Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase, Nat Med, 3, 665, 10.1038/nm0697-665 Katz, 1998, The care of persons with recent sexual exposure to HIV, Ann Intern Med, 128, 306, 10.7326/0003-4819-128-4-199802150-00012 Ministére de l’emploi et de la solidarité (France). Accidents d’exposition au risque de transmission du HIV. En: Prise en charge therapeutique des personnes infectees par le HIV. París: 1999. Disponible en: http://www.sante.gouv.fr/htm/dossiers/sidahop/index_delfra.htm 1998, Swiis Office Féderal de la Santé Publique (OFSP). Profilassi dopo esposizione all’HIV. Raccomandazioni provvisorie concernenti la profilassi dopo esposizione all’HIV al di fuori dell’ambito sanitario, Bulletin de la OFSP, Berna-Swiss, 9, 9 1997, Comissione Nazionale per la lotta contro l’AIDS e le malattie infettive emergenti e riemergenti. Aggiornamento delle Linee-guida per la chemioprofilassi con antiretrovirali dopo esposizione occupazionale ad HIV negli operatori sanitari, Ministerio della Sanità da Italia, Giornale Italiano delle Infezioni Ospedaliere, 4 Puro, 1998, Le pillole del giorno dopo. Consideración sulla posibilita di una profilassi farmacológica dell’infezione da HIV per le esposizioni non occupazionali, Giornale Italiano dell’AIDS, 9, 29 1998, CDC, Centers for Disease ControlPrevention (United States). Public Health Service Statement. Management of Possible Sexual, Injecting-Drug-Use, or Other Non-occupational Exposure to HIV, Including Considerations Related to Antiretroviral Therapy, Morb Mortal Wkly Rep, 47, 1 Lot, 2000 Puro, 2000 Bernasconi, 2000 Kwong, 2000 Torres, 2000 Roland, 2000 Friedman, 2000 Correll, 2000, Non occupational HIV post exposure prophylaxis (PEP) in Australia Almeda, 2001, Conocimientos, actitudes y prácticas (KAP) respecto a la profilaxis post-exposición al VIH no ocupacional (NONOPEP) en Cataluña [Abstract CP05p3]. 6th Congreso Nacional sobre el SIDA, 3-6 abril 2001, Valencia, Pub Of SEISIDA, 12, 10 Sperling, 1996, Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant, N Engl J Med, 335, 1621, 10.1056/NEJM199611283352201 Mastro, 1996, Probabilities of sexual HIV-1 transmission, AIDS, 10, S75, 10.1097/00002030-199601001-00011 Royce, 1997, Sexual transmission of HIV, N Engl J Med, 336, 1072, 10.1056/NEJM199704103361507 Lurie, 1998, Postexposure prophylaxis after nonoccupational HIV exposure: Clinical, ethical, and policy considerations, JAMA, 280, 1769, 10.1001/jama.280.20.1769 Barry, 1999, Postexposure prophylaxis following HIV exposure [carta], JAMA, 281, 1269, 10.1001/jama.281.14.1269 Bamberger, 1999, Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault, Am J Med, 106, 323, 10.1016/S0002-9343(99)00018-2 Li, 1997, Postexposure treatment of HIV [carta], N Engl J Med, 337, 499, 10.1056/NEJM199708143370714 Katz, 1997, Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use, N Engl J Med, 336, 1097, 10.1056/NEJM199704103361512 Gostin, 1994, HIV testing, counseling, and prophylaxis after sexual assault, JAMA, 271, 1436, 10.1001/jama.1994.03510420068036 Cardo, 1997, A case-control study of HIV seroconversion in health care workers after percutaneous exposure, N Engl J Med, 337, 1485, 10.1056/NEJM199711203372101 Robinson, 1993, Arguments against the chemoprophylactic use of zidovudine following occupational exposure to the human immunodeficiency virus, Clin Infect Dis, 16, 357, 10.1093/clind/16.3.357 Zhang, 1999, Sexual transmission and propagation of SIV and HIV in resting and activated CD4+T cells, Science, 286, 1353, 10.1126/science.286.5443.1353 Blauvelt, 1997, The role of skin dendritic cells in the initiation of human immunodeficiency virus infection, Am J Med, 102, 16, 10.1016/S0002-9343(97)00055-7 Clerici, 1994, HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood, JAMA, 271, 42, 10.1001/jama.1994.03510250058035 Descamps, 2000, Mechanisms of Virologic Failure in Previously Untreated HIV-Infected Patients from a trial of Induction-Maintenance Therapy, JAMA, 283, 205, 10.1001/jama.283.2.205 Little, 1999, Reduced antiviral drug susceptibility among patients with primary HIV infection, JAMA, 282, 1142, 10.1001/jama.282.12.1142 Briones, 2001, Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid, J Acquir Immune Defic Syndr, 26, 145, 10.1097/00126334-200102010-00006 Puig, 2000, Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain: The ERASE-2 Study Group, AIDS, 14, 727, 10.1097/00002030-200004140-00012 Hirsch, 2000, Antiretroviral Drug Resistance Testing in Adult HIV-1 Infection: Recommendations of an International AIDS Society-USA Panel, JAMA, 283, 2417, 10.1001/jama.283.18.2417 Beekman, 1997, Combination post-exposure prophylaxis (PEP): A prospective study of HIV-exposed health care workers, Clin Infect Dis, 25, 444 Parkin, 2000, Tolerability and side-effects of post-exposure prophylaxis for HIV infection [carta], Lancet, 355, 722, 10.1016/S0140-6736(99)05005-9 2001, Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures: Worldwide, 1997-2000, Morb Mortal Wkly Rep, 49, 1153 Carpenter, 2000, Antiretroviral Therapy in Adults. Updated Recommendations of the International AIDS Society-USA Panel, JAMA, 283, 381, 10.1001/jama.283.3.381 Eron, 2000, Efficacy, Safety and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection, AIDS, 14, 671, 10.1097/00002030-200004140-00006 Finkelhor, 1990, Sexual abuse in a National survey of adult me and women, Child Abuse Negl, 14, 19, 10.1016/0145-2134(90)90077-7 Ministerio del Interior. Disponible en: http://www.mtas.es/mujer/mcifras/tabla11.htm Centro de Investigaciones Sociológicas. Estudio 2364; Distribuciones marginales del Barómetro de Junio 1999. Disponible en; http://www.cis.es/baros/mar2364.html Gómez de Liaño, 1996 1997, Consell de Col¿legis de Metges de Catalunya